Article
Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.
Bridging Therapeutic Innovation and Dermatology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
State-of-the-State Update: Chronic Hand Eczema
Researchers Develop Recommendations for Hyaluronic Acid Filler Placement in Cases of Hollowness, Volume Deficits